Logo image
Blockage of the Ryanodine Receptor via Azumolene Does Not Prevent Mechanical Ventilation-Induced Diaphragm Atrophy
Journal article   Open access   Peer reviewed

Blockage of the Ryanodine Receptor via Azumolene Does Not Prevent Mechanical Ventilation-Induced Diaphragm Atrophy

Erin E Talbert, Ashley J Smuder, Oh Sung Kwon, Kurt J Sollanek, Michael P Wiggs and Scott K Powers
PloS one, Vol.11(2), pp.e0148161-e0148161
2016
DOI: 10.1371/journal.pone.0148161
PMCID: PMC4744044
PMID: 26849371
url
https://doi.org/10.1371/journal.pone.0148161View
Published (Version of record) Open Access

Abstract

Mechanical ventilation (MV) is a life-saving intervention for patients in respiratory failure. However, prolonged MV causes the rapid development of diaphragm muscle atrophy, and diaphragmatic weakness may contribute to difficult weaning from MV. Therefore, developing a therapeutic countermeasure to protect against MV-induced diaphragmatic atrophy is important. MV-induced diaphragm atrophy is due, at least in part, to increased production of reactive oxygen species (ROS) from diaphragm mitochondria and the activation of key muscle proteases (i.e., calpain and caspase-3). In this regard, leakage of calcium through the ryanodine receptor (RyR1) in diaphragm muscle fibers during MV could result in increased mitochondrial ROS emission, protease activation, and diaphragm atrophy. Therefore, these experiments tested the hypothesis that a pharmacological blockade of the RyR1 in diaphragm fibers with azumolene (AZ) would prevent MV-induced increases in mitochondrial ROS production, protease activation, and diaphragmatic atrophy. Adult female Sprague-Dawley rats underwent 12 hours of full-support MV while receiving either AZ or vehicle. At the end of the experiment, mitochondrial ROS emission, protease activation, and fiber cross-sectional area were determined in diaphragm muscle fibers. Decreases in muscle force production following MV indicate that the diaphragm took up a sufficient quantity of AZ to block calcium release through the RyR1. However, our findings reveal that AZ treatment did not prevent the MV-induced increase in mitochondrial ROS emission or protease activation in the diaphragm. Importantly, AZ treatment did not prevent MV-induced diaphragm fiber atrophy. Thus, pharmacological inhibition of the RyR1 in diaphragm muscle fibers is not sufficient to prevent MV-induced diaphragm atrophy.
Animals Calcium Channel Blockers - pharmacology Diaphragm - drug effects Diaphragm - pathology Enzyme Activation - drug effects Female Imidazoles - pharmacology Mitochondria - drug effects Mitochondria - metabolism Muscular Atrophy - enzymology Muscular Atrophy - etiology Muscular Atrophy - metabolism Muscular Atrophy - prevention & control Oxazoles - pharmacology Peptide Hydrolases - metabolism Rats Rats, Sprague-Dawley Reactive Oxygen Species - metabolism Respiration, Artificial - adverse effects Ryanodine Receptor Calcium Release Channel - metabolism

Details

Metrics

Logo image